Literature DB >> 33778414

Ivermectin as a potential therapeutic in COVID-19.

Juan Segura-Aguilar1, Yousef Tizabi2.   

Abstract

Entities:  

Year:  2020        PMID： 33778414      PMCID： PMC7993655     

Source DB:  PubMed          Journal:  Clin Pharmacol Transl Med        ISSN： 2572-7656


× No keyword cloud information.
  31 in total

1.  Continuous high-dose ivermectin appears to be safe in patients with acute myelogenous leukemia and could inform clinical repurposing for COVID-19 infection.

Authors:  Claudio Galvao de Castro; Lauro Jose Gregianin; Jan A Burger
Journal:  Leuk Lymphoma       Date:  2020-07-01

2.  Novel Ionophores Active against La Crosse Virus Identified through Rapid Antiviral Screening.

Authors:  Zachary J Sandler; Mason R Firpo; Oreoluwa S Omoba; Michelle N Vu; Vineet D Menachery; Bryan C Mounce
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

3.  Ivermectin is a nonselective inhibitor of mammalian P-type ATPases.

Authors:  Paulo Henrique Cotrim Pimenta; Claudia Lucia Martins Silva; François Noël
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-12-30       Impact factor: 3.000

Review 4.  Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance.

Authors:  R Choudhary; A K Sharma
Journal:  New Microbes New Infect       Date:  2020-04-22

5.  The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.

Authors:  Leon Caly; Julian D Druce; Mike G Catton; David A Jans; Kylie M Wagstaff
Journal:  Antiviral Res       Date:  2020-04-03       Impact factor: 5.970

6.  Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia.

Authors:  Songping Cui; Shuo Chen; Xiunan Li; Shi Liu; Feng Wang
Journal:  J Thromb Haemost       Date:  2020-05-06       Impact factor: 5.824

7.  Ivermectin and COVID-19: A report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors' responses.

Authors:  Mike Bray; Craig Rayner; François Noël; David Jans; Kylie Wagstaff
Journal:  Antiviral Res       Date:  2020-04-21       Impact factor: 5.970

8.  Genomic variance of Open Reading Frames (ORFs) and Spike protein in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Authors:  Ping-Hsing Tsai; Mong-Lien Wang; De-Ming Yang; Kung-How Liang; Shih-Jie Chou; Shih-Hwa Chiou; Ta-Hsien Lin; Chin-Tien Wang; Tai-Jay Chang
Journal:  J Chin Med Assoc       Date:  2020-08       Impact factor: 2.743

9.  "COVID-19: diagnosis, management and prognosis": a new topical collection of Internal and Emergency Medicine.

Authors:  Riccardo Polosa; Michele Spinicci; Domenico Prisco
Journal:  Intern Emerg Med       Date:  2020-07-30       Impact factor: 3.397

10.  Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen.

Authors:  Fatemeh Heidary; Reza Gharebaghi
Journal:  J Antibiot (Tokyo)       Date:  2020-06-12       Impact factor: 2.649
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.